Objective: We aimed to investigatethe evolution of depression and anxietyin a large Parkinson’s disease (PD) cohort and explore the related plasma biomarkers.

Background: Depression and anxietyare common non-motor symptoms in PDand have great impact on quality of life. However, plasma biomarkers fordepression and anxiety are lacking.

Method: A total of 184 PD patients were included in the prospective cohort study and followed-up annually for 2 years.Plasma biomarkers, including glial fibrillary acidic protein (GFAP), amyloid-beta (Aβ), p-tau181, and neurofilament light chain (NfL) were measured at each visit. Depression was evaluated usingtheHamilton Depression Rating Scale (HDRS). Patients with a score of more than 20 were considered to have depression. Anxiety was evaluated usingtheHamilton Anxiety Rating Scale (HARS). Patients with a score of more than 14 were considered to have anxiety.

Results: The HDRS scores in PD decreased from 7.70± 7.12at baseline to 6.46 ± 5.38 after 2 years, and the HARSscoresdecreased from 6.14± 6.14 at baseline to 5.81± 5.27 after 2 years.The generalized estimating equations model showed that the presence ofdepression was associated withplasma NfL levels (OR 1.068 [1.016–1.123], p=0.010) and GFAP levels (OR 1.016 [1.005–1.028], p=0.005). Thepresence ofanxiety was associated withplasma NfL levels (OR 1.076 [1.021–1.134], p=0.006).Thelinear mixed-effects model showed that HDRS scores were significantlyassociated withplasma NfLlevels(β 0.113 [0.015–0.211], p=0.024) and GFAP levels(β 0.021 [0.0005–0.042], p=0.045). HARS scores were significantly associated withplasma NfL levels (β 0.163 [0.071–0.255], p=0.001).

Conclusion: Plasma NfL levels correlated with both depressionand anxietyin PD, while plasma GFAP levels correlated with only depression in PD.

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/longitudinal-assessment-of-evolution-and-plasma-biomarkers-for-depression-and-anxiety-in-parkinsons-disease/